The 7 treatments included in the study were amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil.
Jornay PM utilizes the proprietary Delexis drug delivery platform which consists of 2 functional film coatings: the first layer delays the initial drug release for up to 10 hours and the second layer helps control the release rate of the active ingredient throughout the day.
These results indicate an association between adolescent engagement in digital media activities and subsequent ADHD symptoms.
There is a modest, but statistically significant, association between higher frequency of digital media use and subsequent symptoms of ADHD among adolescents.
These findings illustrate potential gains of reducing the number of preterm births and the importance of providing custom support to children born preterm to prevent neurodevelopmental problems.
Nonstimulants may be an appropriate alternative in cases in which co-occurring conditions might prevent the administration of stimulants.
The high risk for several neuropsychiatric and developmental disorders supports more extended use of genetic testing in child and adolescent psychiatry.
Early preterm birth is associated with a higher level of ADHD symptoms in preschool children.
Investigators conducted a retrospective observational study to assess the impact of psychostimulant medication on BMI and height in a group of children and adolescents with ADHD.
Medication continuity in youth with ADHD is affected by several potentially modifiable factors that could be productive targets of intervention for pediatricians.
Exposure to hypertensive disorders of pregnancy may be associated with an increase in the risk for ASD and ADHD in offspring.
A chart outlining pharmacotherapies for ADHD, including information on form, strength, maximum dosages and administration.
These findings offer preliminary evidence of the validity of the short UPPS-P-C to screen for impulsivity traits in both typically developing children and in those with ADHD.
While the authors discovered no "sensitive period," the number of stressful events was moderately associated with the severity of attention-deficit/hyperactivity disorder symptoms.
There are considerable gaps in knowledge relating to the effectiveness of nonpharmacologic treatments for ADHD in pediatric patients.
The results of the study point to effective alternatives to psychopharmacologic treatments with methylphenidate for patients who experience nonresponse, contraindications, or adverse events, or for patients who prefer nonpsychopharmacologic treatments.
Just as we need to be able to identify who is likely to benefit from treatment, we also need to be able to identify those who are most at risk of experiencing adverse events.
These findings can inform clinical practice in that type 2 diabetes should be considered in ADHD even in the absence of other known risk factors.
While overall prescribing of medications decreased compared with the early 2000s, the use of ADHD medication, asthma medicine, and contraceptive use increased while use of antibiotics, antihistamines, and upper respiratory combination medications decreased.
For children with ADHD, participation in after-school activities is associated with reduced odds of moderate-to-severe ADHD.
In pediatric patients with ADHD, treatment with dasotraline 4 mg/day was effective in treating a range of ADHD-related symptoms and behaviors.
ADHD's many deficits cannot be ameliorated by pharmacotherapy alone. Researchers and clinicians are investigating computer interventions and physical activity that get to the root of the ADHD domain, such as inattention, memory, or time management.
The results of this study suggest that children prenatally exposed to substances should receive early mental health assessment.
These data confirmed the increased risk for psychiatric disorders in women with PCOS, and indicated an increased risk for ADHD and ASD in their children.
These results may be used to improve early identification of at-risk siblings based on a proband diagnosis of ADHD.
Recognizing the increased risk for mood disorders in children with ASD and ADHD may be useful for clinicians and parents in developing proper screening and treatment strategies.
If replicated, the novel findings in this study may have important implications for assessing sluggish cognitive tempo in ADHD.
Abstinence relieves symptoms associated with attention-deficit/hyperactivity disorder among patients with polysubstance use disorder.
Investigators sought to determine the risk for developing secondary ADHD 5 to 10 years after traumatic brain injury in children and adolescents.
Clinician awareness of this issue is essential in order to continue providing effective treatment while attempting to reduce abuse of these prescription drugs.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- Atypical Symptom Presentations in Pediatric OCD
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Digital Media Engagement Associated With ADHD Symptoms in Adolescents
- Strong Social Networks May Mitigate the Effects of Childhood Adversity
- Light Therapy Effective for Older Adults with Nonseasonal Depression
- AMA Adopts Policy on Augmented Intelligence
- Parental Belief in Religion Lowers Child Suicide Risk
- Appetitive Symptoms, Fluoxetine, and Light Therapy: Predicting Treatment Response for Nonseasonal Major Depression
- Bipolar Disorder Patients Benefit From Coping Strategies for Amplified Emotionality